Saudi Arabia is set to reinforce its ambition to become a global life sciences hub as CPHI Middle East and BIO Middle East convene industry leaders, investors and policymakers in the Kingdom.

The twin gatherings bring together pharmaceutical manufacturers, biotechnology firms, contract development organisations, regulators and venture capital groups at a time when Saudi Arabia is accelerating investment in healthcare, research and advanced manufacturing.

Officials view the events as an opportunity to showcase the Kingdom’s expanding capabilities across drug production, clinical research and biotechnology innovation.

Over recent years, Saudi Arabia has increased spending on healthcare infrastructure while introducing regulatory reforms designed to attract foreign direct investment and encourage local production of medicines and vaccines.

Industrial zones dedicated to pharmaceuticals and medical devices have been expanded, with incentives aimed at strengthening supply chain resilience and reducing reliance on imports.

Industry executives attending the conferences are expected to explore partnerships in areas such as biosimilars, advanced therapeutics, digital health and precision medicine.

Saudi authorities have emphasised collaboration between domestic research institutions and international firms to build a knowledge-based ecosystem that can compete globally.

The Kingdom’s broader economic transformation strategy has placed healthcare and biotechnology among priority sectors for diversification.

Large-scale public investment funds and private sector participation are being channelled into research facilities, start-ups and manufacturing capacity, while workforce development programmes seek to expand specialised scientific talent.

By hosting prominent industry forums, Saudi Arabia aims to position itself not only as a significant regional market but also as a centre for production, innovation and export across the Middle East and beyond.

Analysts note that sustained regulatory clarity, intellectual property protection and research funding will be critical in translating conference momentum into long-term industrial growth.

As global pharmaceutical supply chains continue to evolve, the convergence of CPHI Middle East and BIO Middle East highlights Saudi Arabia’s determination to anchor itself within the international life sciences landscape.